Sectoral Asset Management Inc. Boosts Stake in Merck & Co., Inc. $MRK

Sectoral Asset Management Inc. raised its position in Merck & Co., Inc. (NYSE:MRK) by 30.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,400 shares of the company’s stock after buying an additional 5,000 shares during the period. Merck & Co., Inc. makes up about 1.8% of Sectoral Asset Management Inc.’s holdings, making the stock its 19th biggest holding. Sectoral Asset Management Inc.’s holdings in Merck & Co., Inc. were worth $2,253,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MRK. Kingdom Financial Group LLC. purchased a new position in Merck & Co., Inc. in the fourth quarter valued at about $25,000. United Financial Planning Group LLC purchased a new position in Merck & Co., Inc. in the third quarter valued at about $31,000. High Note Wealth LLC boosted its holdings in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares during the last quarter. Tucker Asset Management LLC purchased a new position in Merck & Co., Inc. in the fourth quarter valued at about $34,000. Finally, Wealth Watch Advisors INC purchased a new position in Merck & Co., Inc. in the third quarter valued at about $34,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

MRK has been the subject of a number of analyst reports. Wall Street Zen downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. JPMorgan Chase & Co. increased their price target on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a report on Monday, April 6th. Citigroup initiated coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price target for the company. Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a report on Monday, March 30th. Finally, Wells Fargo & Company reduced their price target on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $128.18.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and partner Sichuan Kelun-Biotech reported encouraging late-stage lung cancer data for a Keytruda combination, with the treatment beating Keytruda alone and improving confidence in Merck’s cancer pipeline. Kelun, Merck’s lung cancer combo improves survival in late-stage China trial
• Positive Sentiment: The European Medicines Agency’s CHMP issued a positive opinion for Keytruda plus Padcev as a perioperative treatment for certain bladder cancer patients, which could expand the drug pair’s commercial reach if formally approved. Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev
• Positive Sentiment: Additional coverage highlighted positive EU recommendations and trial momentum across Merck’s oncology portfolio, suggesting the company is building new growth drivers ahead of future Keytruda patent pressure. Merck stock jumps as Keytruda combo trials boost cancer pipeline
• Neutral Sentiment: Some commentary noted Gardasil sales remain weak due to soft demand in China and other markets, which is a reminder that Merck still has headwinds outside oncology. Will Weak Gardasil Sales Continue to Ail MRK’s Vaccines Sales in 2026?
• Neutral Sentiment: Merck’s recent run-up also reflects broader investor optimism after strong quarterly results and improving sentiment around its pipeline, rather than a single one-day event. Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $122.55 on Monday. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a one year low of $75.40 and a one year high of $125.14. The company’s 50-day simple moving average is $115.92 and its 200-day simple moving average is $110.41. The stock has a market capitalization of $302.67 billion, a price-to-earnings ratio of 34.52, a PEG ratio of 2.76 and a beta of 0.18.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter last year, the company posted $2.22 earnings per share. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities analysts anticipate that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.